Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SSRI Treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects
Autore:
Pace-Schott, EF; Gersh, T; Silvestri, R; Stickgold, R; Salzman, C; Hobson, JA;
Indirizzi:
Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, Dept Psychiat,Lab Neurophysiol, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 t,Lab Neurophysiol, Boston, MA 02115 USA Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, Dept Psychiat,Psychopharmacol Program, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 opharmacol Program, Boston, MA 02115 USA Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol, Boston, MA USA Harvard Univ Boston MA USA am & Womens Hosp, Dept Neurol, Boston, MA USA
Titolo Testata:
JOURNAL OF SLEEP RESEARCH
fascicolo: 2, volume: 10, anno: 2001,
pagine: 129 - 142
SICI:
0962-1105(200106)10:2<129:STSDRF>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; EYE-MOVEMENT SLEEP; REM-SLEEP; DEPRESSED-PATIENTS; MAJOR DEPRESSION; NREM SLEEP; FLUOXETINE TREATMENT; INDUCED NIGHTMARES; PAROXETINE;
Keywords:
dreaming; fluvoxamine; paroxetine; serotonin reuptake inhibitors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
77
Recensione:
Indirizzi per estratti:
Indirizzo: Pace-Schott, EF Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, DeptPsychiat,Lab Neurophysiol, 74 Fenwood Rd, Boston, MA 02115 USA Harvard Univ 74 Fenwood Rd Boston MA USA 02115 A 02115 USA
Citazione:
E.F. Pace-Schott et al., "SSRI Treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects", J SLEEP RES, 10(2), 2001, pp. 129-142

Abstract

Clinical lore and a small number of published studies report that the selective serotonin reuptake inhibitors (SSRIs) intensify dreaming. This study examines the dream effects of paroxetine and fluvoxamine in order to both increase clinical knowledge of these agents and to test an important potential method for probing the relationship between REM sleep neurobiology and dreaming in humans. Fourteen normal, paid volunteers (4 males, 10 females; mean age 27.4 year, range 22-39) free of medical or neuropsychiatric symptoms as well as of psychotropic or sleep affecting drugs completed a 31-day home-based study consisting of: 7 days drug-free baseline; 19 days on either 100 mg fluvoxamine (7 Ss) or 20 mg paroxetine (7 Ss) in divided morning andevening doses; and 5 days acute discontinuation. Upon awakening, subjects wrote dream reports, self-scored specific emotions in their reports and rated seven general dream characteristics using 5-point Likert scales. Dream reports were independently scored for bizarreness, movement and number of visual nouns by three judges. REM sleep-related measures were obtained using the Nightcap ambulatory sleep monitor. Mean dream recall frequency decreased during treatment compared with baseline. Dream report length and judge-rated bizarreness were greater during acute discontinuation compared with both baseline and treatment and this effect was a result of the fluvoxamine-treated subjects. The subjective intensity of dreaming increased during both treatment and acute discontinuation compared with baseline. Propensity to enter REM sleep was decreased during treatment compared with baseline and acute discontinuation and the intensity of REM sleep increased during acute discontinuation compared with baseline and treatment. The decrease in dream frequency during SSRI treatment may reflect serotonergic REM suppression while the augmented report length and bizarreness during acute SSRI discontinuation may reflect cholinergic rebound from serotonergic suppression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 10:47:44